http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Adjuvant Therapy for Esophageal Squamous Cell Carcinoma
선종무 대한흉부외과학회 2020 Journal of Chest Surgery (J Chest Surg) Vol.53 No.4
Adjuvant therapy for completely resected esophageal squamous cell carcinoma is less commonly applied in clinical practice than neoadjuvant therapy, but it plays a substantial role in improving survival for esophageal cancer patients. This article presents a concise re- view of the evidence regarding adjuvant therapy for esophageal squamous cell carcinoma and future directions, particularly immunotherapy.
심부정맥 혈전증과 폐 색전증으로 발현된 특발성 과호산구증가증 1례
선종무,이종석,이재훈,김진수,김태민,김태용,한세원,홍용상,윤성수,김병국,박선양 대한혈액학회 2004 Blood Research Vol.39 No.3
We report a case of idiopathic hypereosinophilic syndrome (HES) presenting with deep vein thrombosis and subsequent massive pulmonary embolism. The eosinophilia and thromboembolism improved dramatically with systemic corticosteroid and anticoagulation therapy. However, the early and rapid tapering of corticosteroid, in a state of normal eosinophil count and therapeutic PT level, aggravated thromboembolism. An immediate retrial of corticosteroid made disease improve again. The etiology of HES and the pathogenesis of thrombus formation in HES still remain uncertain but corticosteroid in treatment of HES is yet cardinal and should be maintained for a prolonged period of time. (Korean J Hematol 2004;39:196~199)
선종무 ( Jong Mu Sun ),정현채 ( Hyun Chae Jung ) 대한소화기학회 2004 대한소화기학회지 Vol.44 No.2
Carcinoid tumors originate from the neuroendocrine cells throughout the body and occur most frequently (74%) in the gastrointestinal tract. The clinical course is often indolent but can also be aggressive and resistant to therapy. Clinical manifestations
김내유,선종무,김유정,이근욱,김지현,방수미,김진욱,정숙향,이종석 대한암학회 2010 Cancer Research and Treatment Vol.42 No.4
Purpose Systemic chemotherapy is the only option for patients with unresectable/metastatic hepatocellular carcinoma (HCC) who are not candidates for local/regional treatment. However, the response to such treatment and survival are poor, especially in hepatitis B virus (HBV) endemic areas. The aim of this study was to determine the efficacy of cisplatin-based combination chemotherapy and identify a subgroup of advanced HCC patients with favorable responses. Materials and Methods The medical records of all consecutive patients with unresectable/metastatic HCC who received cisplatin-based combination chemotherapy between January 2003 and October 2009 were reviewed. Time to progression (TTP) and overall survival (OS) were determined using Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify prognostic factors for TTP and OS. Results Data for 46 patients were analyzed. First-line chemotherapies consisted of cisplatin-based combination treatment with doxorubicin, fluoropyrimidines and gemcitabine. The response rate for all patients was 4.3%. The median TTP and OS were 1.8 (95%confidence interval [CI], 1.1 to 2.5) and 7.2 (95% CI, 3.0 to 11.5) months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status (PS), Child classification, Cancer of the Liver Italian Program (CLIP) score and portal vein thrombosis (PVT) were identified by univariate analyses as prognostic factors for TTP and OS. ECOG PS (hazard ratio [HR], 4.51; 95%CI, 1.61 to 12.6; p=0.004) and PVT (HR, 2.12; 95%CI, 1.10 to 4.11; p=0.026) were independent prognostic factors for TTP. Conclusion Cisplatin-based combination chemotherapy in patients with advanced HCC has a low response rate and short TTP regardless of the chemotherapy regimen used. Patients with a good ECOG PS and without PVT can be considered candidates for cisplatin-based combination chemotherapy.